616.234.5000

Fan Xuan, Ph.D.

Fan Xuan, Ph.D.
Postdoctoral fellow, Wen Laboratory
616.234.5271

Biography

Dr. Fan Xuan earned his B.Sc. in bioengineering from Shandon Jianzhu University, followed by an M.Sc. and a Ph.D. in biochemistry and molecular biology from Southwest University. His graduate research focused on neurological cancers, with a specific interest in epigenetic regulation in glioblastoma. In 2018, he accepted a postdoctoral fellowship with Dr. Xiaobing Shi at UT MD Anderson Cancer Center and subsequently moved with his lab to Van Andel Research Institute. He is now in the lab of Dr. Hong Wen at VARI, where he studies the histone reader ENL YEATS domain mutation in Wilms tumors.

 

Current research focus

My work focuses on the histone reader ENL YEATS domain mutation in Wilms tumor. Recently, some ENL mutations were identified in Wilms tumors, and we are interested in the relationship between these mutations and Wilms tumors. Mutations in the YEATS domain structurally alters ENL proteins, resulting in a change of downstream gene expression. Clarifying the underlying mechanism will help improve Wilms tumor therapy.

Education & Training

Postdoctoral fellow, Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center (Advisor: Dr. Xiaobing Shi)

Ph.D. in biochemistry and molecular biology, Southwest University (Advisor: Dr. Hongjuan Cui)
Thesis: Homeobox C9 suppresses Beclin1-mediated autophagy in glioblastoma by directly inhibiting the transcription of death-associated protein kinase 1

M.Sc. in biochemistry and molecular biology, Southwest University (Advisor: Dr. Hongjuan Cui)

B.Sc. in bioengineering, Shandong Jianzhu University

Awards

Miyoshi Outstanding Graduate of Southwest University (2017)

National Scholarship of China (2016)

Third-Class Scholarship of Shandong Jianzhu University (2010)

Individual Scholarships of Shandong Jianzhu University (2009)

Publications

Xuan F, Huang M, Zhao E, Cui H*. 2018. MINA53 deficiency leads to glioblastoma cell apoptosis via inducing DNA replication stress and diminishing DNA damage response. Cell Death Dis 9(11):1062.

Huang M, Xuan F, Liu W, Cui HJ*. 2017. MINA controls proliferation and tumorigenesis of glioblastoma by epigenetically regulating cyclins and CDKs via H3K9me3 demethylation. Oncogene 36(3):387–396.

Xuan F, Huang M, Liu W, Ding H, Yang L, Cui H. 2016. Homeobox C9 suppresses Beclin1-mediated autophagy in glioblastoma by directly inhibiting the transcription of death-associated protein kinase 1. Neuro Oncol 18(6):819–829.

Yang L, Ke XX, Xuan F, Tan J, Hou J, Wang M, Cui H, Zhang Y. 2016. PHOX2B is associated with neuroblastoma cell differentiation. Cancer Biother Radiopharm 31(2):44–51.

Datar I, Qiu XL, Ma HZ, Yeung M, Aras S, de la Serna I, Al-Mulla F, Tan TZ, Thiery JP, Trumbly R, Xuan F, Cui HJ, Yeung KC. 2016. RKIP regulates CCL5 expression to inhibit breast cancer invasion and metastasis by controlling macrophage infiltration. 6(36):39050–39061.

Wang M, Liu Y, Zou JH, Yang R, Xuan F, Wang Y, Gao N, Cui HJ. 2015. Transcriptional co-activator TAZ sustains proliferation and tumorigenicity of neuroblastoma by targeting CTGF and PDGF-beta. Oncotarget 6:9517–9530.

Zhang K, Tan J, Xu M, Su JJ, Hu RJ, Chen YB, Xuan F, Yang R, Cui HJ. 2014. A novel granulocyte-specific alpha integrin is essential for cellular immunity in the silkworm Bombyx mori. J Insect Physiol 71:61–67.